Pharmafile.com’s weekly COVID-19 news round-up
pharmafile | November 25, 2020 | News story | Research and Development |Â Â Â
The coronavirus news this week sees more companies release their coronavirus vaccine results, with Pfizer and BioNTech backing up their promising interim Phase 3 data showing 90% efficacy for their COVID-19 vaccine candidate with a final analysis of the findings, showing an even higher level of efficacy, while the National Research Center for Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF) have released a statement saying the Sputnik V vaccine for COVID-19 has a 91.4% efficacy after 28 days, and over 95% efficacy 42 days after the first dose.
1. Pfizer/BioNTech’s COVID-19 vaccine shows up to 95% efficacy in final analysis, including in over-65s – Published on 18/11/20
Pfizer and BioNTech have backed up their promising interim Phase 3 data showing 90% efficacy for their COVID-19 vaccine candidate with a final analysis of the findings, showing an even higher level of efficacy, and in crucial sub-populations.
2. FDA approves first at-home coronavirus self-testing kit – Published on 18/11/20
The FDA has issued an Emergency Use Authorization for the first coronavirus self-testing kit for use at home that produces rapid results.
3. Russia’s Sputnik COVID-19 vaccine has 91.4% efficacy after 28 days, new interim data show – Published on 24/11/20
The National Research Center for Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF) have released a statement saying the Sputnik V vaccine for COVID-19 has a 91.4% efficacy after 28 days, and over 95% efficacy 42 days after the first dose.
4. Five Chinese coronavirus vaccines in overseas clinical trials – Published on 19/11/20
Five different coronavirus vaccines from China are being tested in Phase 3 trials around the world.
5. Pfizer launches pilot delivery programme for its coronavirus vaccine – Published on 17/11/20
Pfizer is set to launch its first delivery programme for the COVID-19 vaccine it developed with BioNTech. It will be located in multiple sites across America; the company said it has selected New Mexico, Tennessee, Rhode Island and Texas for the programme because of their differences in size and immunisation infrastructure.
